ASCO 2025, bladder cancer, muscle-invasive bladder cancer (MIBC), SURE-01 trial, radical cystectomy, neoadjuvant sacituzumab govitecan (SG), monotherapy, sacituzumab govitecan followed by radical ...

SNMMI 2025 positive predictive value of 18F-piflufolastat PET/CT, prostate/prostatic bed, patients with biochemical recurrence when stratified by PSA level at the time of imaging, CONDOR study.

SNMMI 2025, post-177Lu therapy, WB SPECT/CT, WB SPECT/CT Studies Post Lu 177 Therapy, 177Lu-PSMA SPECT, StarGuide scanner, 177Lu-PSMA-617 radiopharmaceutical therapy.

Daniel Spratt and Alicia Morgans discuss clinical outcomes of patients with Gleason score 9-10 prostate cancer after definitive treatment.

WCET 2024 optimizing stone treatment, Michelle Jo Semins, laser modalities, world’s first ureteroscopy and laser lithotripsy, MOSES technology.

(UroToday.com) The 2025 SNMMI annual meeting featured a prostate cancer and molecular imaging session and a presentation by Dr. Jiarou Wang discussing the first human study of 68 Ga-P17-079 in ...

PSMA and Beyond PSMA-targeted prostate biopsy, MRI-guided biopsy, PIRADS 2 lesion, 68Ga-PSMA-11, PSMA guided fusion biopsy, PIRADS delineation, SUVmax and PRIMARY score.

AUA 2025 thermal safety of high-powered lasers during endoscopic stone surgery, renal calyceal, parenchymal temperatures, laser lithotripsy, 60W Super-Pulse Thulium Fiber Laser (TFL), 120W ...